Monoclonal Antibodies in Neurology: Current State and Future Development

Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B lymphocytes, cytokines, complement, and adhesion molecules. In...

Full description

Saved in:
Bibliographic Details
Published in:Human physiology Vol. 48; no. 8; pp. 932 - 937
Main Author: Zakharova, M. N.
Format: Journal Article
Language:English
Published: Moscow Pleiades Publishing 01.12.2022
Springer Nature B.V
Subjects:
Alzheimer's disease
Autoimmune diseases
Biomedical and Life Sciences
Biomedicine
CD19 antigen
CD20 antigen
Demyelinating diseases
Demyelination
Human Physiology
Life Sciences
Lymphocytes B
Monoclonal antibodies
Multiple sclerosis
Nanobodies
Neurodegenerative diseases
Neuromyelitis
Parenchyma
β-Amyloid
nanobodies
Alzheimer’s disease
demyelinating diseases
multiple sclerosis
neuromyelitis optica
monoclonal antibodies
ISSN:0362-1197, 1608-3164
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer’s disease, in which the target for monoclonal antibodies is pathologically altered beta-amyloid protein that accumulates in the brain parenchyma. This review presents new therapeutic approaches to the use of antibody fragments, with an emphasis on their new class, nanobodies. Special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway.
AbstractList Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer’s disease, in which the target for monoclonal antibodies is pathologically altered beta-amyloid protein that accumulates in the brain parenchyma. This review presents new therapeutic approaches to the use of antibody fragments, with an emphasis on their new class, nanobodies. Special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway.
Author Zakharova, M. N.
Author_xml – sequence: 1
  givenname: M. N.
  surname: Zakharova
  fullname: Zakharova, M. N.
  email: vincera@vincera.ru
  organization: Research Center of Neurology
BookMark eNp1kMFLwzAYxYNMcJv-Ad4Cnqv5kjZJvY3pnDD1MD2XtP0yOrpkJq2w_96OCR7E0zu833s83oSMnHdIyDWwWwCR3q2ZkBwgV5wzzZjiZ2QMkulEgExHZHy0k6N_QSYxbtmAgM7HZPnina9a70xLZ65rSl83GGnj6Cv2wbd-c7in8z4EdB1dd6ZDalxNF33XB6QP-IWt3-8G85KcW9NGvPrRKflYPL7Pl8nq7el5Plsl1bCTJ4aDsmWptOS1yFKdCjTWKo6l0IhgpS5zCXltM6hKISQyldV1msnUcqmMEVNyc-rdB__ZY-yKre_DMD8WXEmtBDAuBgpOVBV8jAFtsQ_NzoRDAaw4Hlb8OWzI8FMmDqzbYPht_j_0DQSWbaY
Cites_doi 10.1177/1756286418761697
10.1371/journal.pone.0165964
10.1056/NEJMoa1606468
10.1080/13543784.2018.1442437
10.3389/fncel.2014.00344
10.1111/jth.13716
10.1146/annurev-biochem-063011-092449
10.1080/13543784.2018.1443077
10.1038/363446a0
10.1016/j.biopsych.2017.08.010
10.4049/jimmunol.1501761
ContentType Journal Article
Copyright Pleiades Publishing, Inc. 2022. ISSN 0362-1197, Human Physiology, 2022, Vol. 48, No. 8, pp. 932–937. © Pleiades Publishing, Inc., 2022. Russian Text © The Author(s), 2018, published in Annaly Klinicheskoi i Eksperimental’noi Nevrologii, 2018, Vol. 12, No. 5S, pp. 99–104.
Copyright_xml – notice: Pleiades Publishing, Inc. 2022. ISSN 0362-1197, Human Physiology, 2022, Vol. 48, No. 8, pp. 932–937. © Pleiades Publishing, Inc., 2022. Russian Text © The Author(s), 2018, published in Annaly Klinicheskoi i Eksperimental’noi Nevrologii, 2018, Vol. 12, No. 5S, pp. 99–104.
DBID AAYXX
CITATION
NAPCQ
DOI 10.1134/S0362119722080072
DatabaseName CrossRef
ProQuest Nursing and Allied Health Premium
DatabaseTitle CrossRef
Nursing & Allied Health Premium
DatabaseTitleList
Nursing & Allied Health Premium
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1608-3164
EndPage 937
ExternalDocumentID 10_1134_S0362119722080072
GroupedDBID -56
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
29I
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
4.4
408
409
40D
40E
5GY
5VS
67N
67Z
6NX
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHQN
ABIVO
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSNA
ACZOJ
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AEOHA
AEPYU
AETLH
AEVLU
AEXYK
AFBBN
AFGCZ
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BDATZ
BGNMA
BSONS
CAG
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
DXH
EBLON
EBS
EIOEI
EJD
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IHE
IJ-
IKXTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAK
LLZTM
M4Y
MA-
N2Q
NB0
NPVJJ
NQJWS
NU0
O9-
O93
O9I
O9J
OAM
OVD
PF0
PT4
QOR
QOS
R89
R9I
RNI
ROL
RPX
RSV
RZC
RZE
S16
S1Z
S27
S3A
S3B
SAP
SBL
SDH
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
SZN
T13
TEORI
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
XU3
YLTOR
ZMTXR
ZOVNA
ZXP
~A9
7RV
7X7
8FI
AAPKM
AAYXX
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFKRA
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
BBNVY
BENPR
BHPHI
CCPQU
CITATION
FYUFA
HCIFZ
HMCUK
M1P
M7P
NAPCQ
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PSQYO
UKHRP
ID FETCH-LOGICAL-c1132-a217fbb7862d354843eaff72eb38ee1f68b9619df51cb336e075dd4564f267aa3
IEDL.DBID RSV
ISSN 0362-1197
IngestDate Tue Oct 07 07:01:57 EDT 2025
Sat Nov 29 05:55:21 EST 2025
Fri Feb 21 02:44:02 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords nanobodies
Alzheimer’s disease
demyelinating diseases
multiple sclerosis
neuromyelitis optica
monoclonal antibodies
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1132-a217fbb7862d354843eaff72eb38ee1f68b9619df51cb336e075dd4564f267aa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
PQID 2768731023
PQPubID 2043765
PageCount 6
ParticipantIDs proquest_journals_2768731023
crossref_primary_10_1134_S0362119722080072
springer_journals_10_1134_S0362119722080072
PublicationCentury 2000
PublicationDate 20221200
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 20221200
PublicationDecade 2020
PublicationPlace Moscow
PublicationPlace_xml – name: Moscow
– name: New York
PublicationTitle Human physiology
PublicationTitleAbbrev Hum Physiol
PublicationYear 2022
Publisher Pleiades Publishing
Springer Nature B.V
Publisher_xml – name: Pleiades Publishing
– name: Springer Nature B.V
References Rissiek, Koch-Nolte, Magnus (CR8) 2014; 8
Hamers-Casterman, Atarhouch, Muylder-mans (CR7) 1993; 363
Paul, Murphy, Pardo, Levy (CR4) 2018; 27
Peyvandi, Scully (CR9) 2017; 15
Butler, Joshi, De Genst (CR10) 2016; 11
CR6
CR5
Gajofatto, Turatti (CR1) 2018; 27
Muyldermans (CR11) 2013; 82
Forsthuber, Cimbora, Ratchford (CR3) 2018; 11
Montalban, Hauser, Kappos (CR2) 2017; 376
A. Gajofatto (84493_CR1) 2018; 27
X. Montalban (84493_CR2) 2017; 376
84493_CR5
F. Peyvandi (84493_CR9) 2017; 15
84493_CR6
D.C. Butler (84493_CR10) 2016; 11
F. Paul (84493_CR4) 2018; 27
B. Rissiek (84493_CR8) 2014; 8
S. Muyldermans (84493_CR11) 2013; 82
T.G. Forsthuber (84493_CR3) 2018; 11
C. Hamers-Casterman (84493_CR7) 1993; 363
References_xml – volume: 11
  start-page: 1756286418761697
  year: 2018
  ident: CR3
  article-title: B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
  publication-title: Ther. Adv. Neurol. Disord.
  doi: 10.1177/1756286418761697
– volume: 11
  start-page: e0165964
  year: 2016
  ident: CR10
  article-title: Bifunctional anti-non-amyloid component α-synuclein nanobodies are protective
  publication-title: PloS One
  doi: 10.1371/journal.pone.0165964
– ident: CR6
– volume: 376
  start-page: 209
  year: 2017
  ident: CR2
  article-title: Ocrelizumab versus placebo in primary progressive multiple sclerosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606468
– ident: CR5
– volume: 27
  start-page: 273
  year: 2018
  ident: CR1
  article-title: Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1080/13543784.2018.1442437
– volume: 8
  start-page: 344
  year: 2014
  ident: CR8
  article-title: Nanobodies as modulators of inflammation: potential applications for acute brain injury
  publication-title: Front. Cell. Neurosci.
  doi: 10.3389/fncel.2014.00344
– volume: 15
  start-page: 1448
  year: 2017
  ident: CR9
  article-title: Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/jth.13716
– volume: 82
  start-page: 775
  year: 2013
  ident: CR11
  article-title: Nanobodies: natural single-domain antibodies
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev-biochem-063011-092449
– volume: 27
  start-page: 265
  year: 2018
  ident: CR4
  article-title: Investigational drugs in development to prevent neuromyelitis optica relapses
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1080/13543784.2018.1443077
– volume: 363
  start-page: 446
  year: 1993
  ident: CR7
  article-title: Naturally occurring antibodies devoid of light chains
  publication-title: Nature
  doi: 10.1038/363446a0
– volume: 11
  start-page: 175628641876169
  year: 2018
  ident: 84493_CR3
  publication-title: Ther. Adv. Neurol. Disord.
  doi: 10.1177/1756286418761697
– ident: 84493_CR6
  doi: 10.1016/j.biopsych.2017.08.010
– volume: 15
  start-page: 1448
  year: 2017
  ident: 84493_CR9
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/jth.13716
– ident: 84493_CR5
  doi: 10.4049/jimmunol.1501761
– volume: 8
  start-page: 344
  year: 2014
  ident: 84493_CR8
  publication-title: Front. Cell. Neurosci.
  doi: 10.3389/fncel.2014.00344
– volume: 376
  start-page: 209
  year: 2017
  ident: 84493_CR2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606468
– volume: 82
  start-page: 775
  year: 2013
  ident: 84493_CR11
  publication-title: Annu. Rev. Biochem.
  doi: 10.1146/annurev-biochem-063011-092449
– volume: 27
  start-page: 273
  year: 2018
  ident: 84493_CR1
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1080/13543784.2018.1442437
– volume: 363
  start-page: 446
  year: 1993
  ident: 84493_CR7
  publication-title: Nature
  doi: 10.1038/363446a0
– volume: 27
  start-page: 265
  year: 2018
  ident: 84493_CR4
  publication-title: Expert Opin. Invest. Drugs
  doi: 10.1080/13543784.2018.1443077
– volume: 11
  start-page: e0165964
  year: 2016
  ident: 84493_CR10
  publication-title: PloS One
  doi: 10.1371/journal.pone.0165964
SSID ssj0007189
Score 2.226495
Snippet Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets...
SourceID proquest
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 932
SubjectTerms Alzheimer's disease
Autoimmune diseases
Biomedical and Life Sciences
Biomedicine
CD19 antigen
CD20 antigen
Demyelinating diseases
Demyelination
Human Physiology
Life Sciences
Lymphocytes B
Monoclonal antibodies
Multiple sclerosis
Nanobodies
Neurodegenerative diseases
Neuromyelitis
Parenchyma
β-Amyloid
Title Monoclonal Antibodies in Neurology: Current State and Future Development
URI https://link.springer.com/article/10.1134/S0362119722080072
https://www.proquest.com/docview/2768731023
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLink
  customDbUrl:
  eissn: 1608-3164
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0007189
  issn: 0362-1197
  databaseCode: RSV
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PS8MwFH7IFPHij01xOiUH8aAE1zRtWm9DHLs4xKnsVpo0gYGmslXB_94kS50_D3ruawhp8t739b18D-AokBFRQVpgKSKOKWcUJ4YJ4a6QJIhVl0qWu2YTbDhMxuP02t_jntXV7nVK0nnqed8RejayvtZ1ySIW5TDjd5dNtEtsv4ab0f27-zXONq01o6y5T2X-OMTnYLRAmF-Soi7W9Df-NctNWPfQEvXme2ELlqRuQqunDa1-fEXHyBV7ur_oTVi98jn1FgzMsS7FQ-ne1dWEl7awEE00csId1v4ceRkn5LApynWB-k6MBH0oOtqGu_7l7cUA-_4KWNj-8jg3dERxzgypKULDXGgoc6UYMfw6kTJQccJTw68KFQWCh2EsDbwoCqs_o0jM8jzcgYYutdwFZOM8VzIlnEsaq4ATA0xE3GWsCGjERRtO6oXOnuYyGpmjHyHNvi1ZGzr1p8j8iZplxPAiFlqhiTac1ku_ePzrYHt_st6HNWLvN7h6lQ40qumzPIAV8VJNZtNDt9HeAI06yfI
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PS8MwFH7IFPXij01xOjUH8aAU2zRtWm9DHBO3IW7KbqVJExhoKtsU_O9Nstb586DnvoaQJu99X9_L9wCOPBFg6cWZI3jAHMIocSLNhByXC-yF0iWCprbZBO31ouEwvinucU_KavcyJWk99azvCDnrG19ru2Rhg3Ko9ruLRAcsI5h_279_d7_a2calZpQxL1KZPw7xORjNEeaXpKiNNa31f81yA9YKaImas72wCQtCVaHWVJpWP76iY2SLPe1f9Cosd4uceg3a-ljn_CG376rpiOWmsBCNFLLCHcb-HBUyTshiU5SqDLWsGAn6UHS0BXety8FF2yn6Kzjc9Jd3Uk1HJGNUk5rM18yF-CKVkmLNryMhPBlGLNb8KpOBx5nvh0LDiywz-jMShzRN_W2oqFyJHUAmzjMpYsyYIKH0GNbAhIcupZlHAsbrcFIudPI0k9FILP3wSfJtyerQKD9FUpyoSYI1L6K-EZqow2m59PPHvw62-yfrQ1hpD7qdpHPVu96DVWzuOtjalQZUpuNnsQ9L_GU6mowP7KZ7Aw6vzNY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFD7IlOGLl01xOjUP4oNStqZp0_o21DFRx2AqeytNk8BA07FVwX9vkrXO64P43NNQcjnnfD1fvgNw5AofSzfijkh95hBGiRNqJOS0U4HdQLaJoIltNkH7_XA0igZFn9NZyXYvS5LzOw1GpUnlrQmXRQ8S0hoav2s7ZmGT8VDtg5eJ4dEbuD58eHfF2vFGpX6UMS_Kmj8O8TkwLbLNLwVSG3e66__-4g1YK1JO1JnvkU1YEqoG9Y7ScPvpFR0jSwK1f9drUL0tau116OnjnqWPmX1X5WOWGcIhGitkBT2M_Rkq5J2QzVlRojjqWpES9IGMtAX33cu7855T9F1wUtN33kk0TJGMUQ12uKcRDfFEIiXFGneHQrgyCFmkcReXvpsyzwuETjs4N7o0Egc0SbxtqKhMiR1AJv4zKSLMmCCBdBnWCUsatCnlLvFZ2oCTctLjyVxeI7awxCPxtylrQLNclrg4abMYa7xEPSNA0YDTchkWj38dbPdP1odQHVx045ur_vUerGJzBcJSWppQyafPYh9W0pd8PJse2P33Brco1bo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Monoclonal+Antibodies+in+Neurology%3A+Current+State+and+Future+Development&rft.jtitle=Human+physiology&rft.au=Zakharova%2C+M.+N.&rft.date=2022-12-01&rft.issn=0362-1197&rft.eissn=1608-3164&rft.volume=48&rft.issue=8&rft.spage=932&rft.epage=937&rft_id=info:doi/10.1134%2FS0362119722080072&rft.externalDBID=n%2Fa&rft.externalDocID=10_1134_S0362119722080072
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0362-1197&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0362-1197&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0362-1197&client=summon